Pharmacoeconomic analysis of voriconazole vs. caspofungin in the empirical antifungal therapy of febrile neutropenia in Australia

Mycoses, 05/04/2012

Caspofungin appears to have a higher probability of having cost–savings than voriconazole for empirical therapy. The difference between the two medications does not seem to be statistically significant however.

Print Article Summary Cat 2 CME Report